Literature DB >> 435404

Anticoagulant activities of high and low molecular weight heparin fractions.

T W Barrowcliffe, E A Johnson, C A Eggleton, G Kemball-Cook, D P Thomas.   

Abstract

The anticoagulant activities of high and low molecular weight heparin fractions were measured by three assay methods, both in vitro, and after intravenous injection in volunteers. The low molecular weight (LMW) fraction had similar anti-Xa activity in vitro to the high molecular weight (HMW) fraction, but in APTT assays the HMW fraction was about twice as potent. After intravenous injection, the two fractions gave equal heparin levels by anti-Xa assays, but in APTT assays using synthetic substrate S-2222 gave about 20% lower levels than anti-Xa clotting assays for both heparins. Complete protamine neutralization of the post-injection heparin activity was found in APTT and synthetic substrate assays, but about 20% of the clotting anti-Xa effect could not be neutralized. Complete neutralization of the fractions by protamine was shown by all three assays in vitro. This non-neutralizable activity probably accounts for the difference between the anti-Xa clotting and synthetic substrate assays. Studies by crossed immunoelectrophoresis and affinity chromatography indicated that the antithrombin III binding properties of the two fractions were similar.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 435404     DOI: 10.1111/j.1365-2141.1979.tb05894.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  Safety and pharmacokinetics of the low molecular weight heparinoid Org 10172 administered to healthy elderly volunteers.

Authors:  J C Stiekema; H P Wijnand; T G Van Dinther; H C Moelker; J Dawes; A Vinchenzo; H Toeberich
Journal:  Br J Clin Pharmacol       Date:  1989-01       Impact factor: 4.335

2.  ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.

Authors:  I D Bradbrook; H N Magnani; H C Moelker; P J Morrison; J Robinson; H J Rogers; R G Spector; T Van Dinther; H Wijnand
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

3.  A prospective randomized trial of low molecular weight heparin-DHE and conventional heparin-DHE (with acenocoumarol) in patients undergoing gynaecological surgery.

Authors:  R A Steiner; K Keller; T Lüscher; W E Schreiner
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

Review 4.  Haematology in the UK: A 60-year personal perspective.

Authors:  Allan Victor Hoffbrand
Journal:  EJHaem       Date:  2021-05-18

5.  Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis.

Authors:  U Schmitz-Huebner; H Bünte; G Freise; B Reers; C Rüschemeyer; R Scherer; H Schulte; J van de Loo
Journal:  Klin Wochenschr       Date:  1984-04-16

6.  [Use of low molecular-weight heparin in hemodialysis patients].

Authors:  J Schrader; J Rieger; H Müschen; W Stibbe; H Köstering; P Kramer; F Scheler
Journal:  Klin Wochenschr       Date:  1985-01-15

7.  The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides.

Authors:  T W Barrowcliffe; S J Havercroft; G Kemball-Cook; U Lindahl
Journal:  Biochem J       Date:  1987-04-01       Impact factor: 3.857

8.  Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis.

Authors:  V V Kakkar; B Djazaeri; J Fok; M Fletcher; M F Scully; J Westwick
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-06

Review 9.  The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.

Authors:  Andrew D Blann; Chee W Khoo
Journal:  Vasc Health Risk Manag       Date:  2009-08-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.